Stockscreener 앱 받기
142.70
0.41%
-0.59
시간 외 거래:
141.50
-1.20
-0.84%
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance UK
Neurocrine Biosciences Inc (NBIX) Stock Up 3.7% and Still Underv - GuruFocus
Neurocrine Biosciences starts Alzheimer's Phase 2 trial - Mugglehead Investment Magazine
Neurocrine Biosciences Initiates Phase 2 Study of Investigational Compound to Treat Alzheimer's Disease - Yahoo Finance
Neurocrine Biosciences starts Phase 2 trial of NBI-1117567 for mild to moderate Alzheimer's cognitive impairment - Pluang
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease - TradingView
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease - PR Newswire
Wedbush Cuts Price Target on Neurocrine Biosciences to $186 From $194, Keeps Outperform Rating - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance Australia
How New CRENESSITY Data At Neurocrine Biosciences Stock Has Changed Its Investment Story - Simply Wall Street
How New CRENESSITY Data At Neurocrine Biosciences Stock Has Changed Its Investment Story - Simply Wall Street
Neurocrine Biosciences (NBIX) Stock Trades Below Fair Value On Earnings - Yahoo Finance
Is Neurocrine Biosciences (NBIX) Undervalued On Pipeline And Pricing Risks? - Simply Wall Street
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia - PR Newswire
Needham reiterates Buy rating on Neurocrine Biosciences, $204 price target - TradingView
RBC keeps USD 187.00 target for Neurocrine Biosciences stock - ad-hoc-news.de
JPMorgan reports a passive stake in Neurocrine Biosciences (NBIX) - Stock Titan
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
Non-operating income (total) of Neurocrine Biosciences, Inc. – HAN:NB3 - TradingView
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance UK
TD Cowen reiterates Neurocrine Bio stock rating on growth outlook - Investing.com
TD Cowen reiterates Neurocrine Bio stock rating on growth outlook By Investing.com - Investing.com India
Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term - Zacks Investment Research
This Biopharma Stock Offers Compelling Upside After a Pullback - Barron's
Is Neurocrine Biosciences Inc (NBIX) a Bargain After 4.4% Drop? GF Value Says Undervalued - GuruFocus
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - Yahoo Finance Singapore
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For? - Yahoo Finance
Neurocrine Biosciences' Vykat XR Sales Likely to Remain 'Flattish' Near Term, RBC Says - Yahoo Finance
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now? - Zacks Investment Research
Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – FWB:NB3 - TradingView
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term - Zacks Investment Research
BMO Capital Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Cuts Target Price to $150 - Moomoo
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Porterville Recorder
Neurocrine is set to release Q3 results at 1 p.m. Pacific on Nov. 2, then host a call. - Stock Titan
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Yahoo Finance
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Arizona Daily Star
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research
A joint trust holds 50,146 shares for Neurocrine Biosciences (NBIX) medical chief Eiry Roberts. - Stock Titan
Neurocrine Biosciences (NBIX) After New VYKAT XR Data Why The Undervalued Narrative Persists - Simply Wall Street
Neurocrine Biosciences stock fell 1.4 percent before research event - AD HOC NEWS
Neurocrine Biosciences (NASDAQ:NBIX) Stands Out as a Decent Value Stock - ChartMill
Neurocrine names Roberts CMO. Neurocrine Biosciences stock sits 23.07 percent below its high - AD HOC NEWS
Neurocrine Biosciences Shares Jump on Fresh Long-term CRENESSITY Data Catalyst - Moomoo
Moderna, Neurocrine bring back familiar faces; Pharming CEO exits after clashing with board - Endpoints News
Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation - ChartMill
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - Yahoo Finance Australia
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
0.75%
자본화:
|
볼륨(24시간):